Members only

Username:

Password:

International Liver Cancer Association (ILCA)
Avenue de Tervueren, 300
B-1150 Brussels
Belgium
info@ilca-online.org
+32 (0)2 789 2345
+32 (0)2 743 1550

Speakers, Sessions, Symposia

Friday, 4 September
Saturday, 5 September
Sunday, 6 September

General Session

State-of-the-Art Lecture

Symposium

Special Lecture

Industry Symposium

Workshop

TIME	Friday, 4 September
08:30 – 11:15	Registration
08:00 – 11:00	Focused Pre-Meeting Workshops • Basic workshop: Current frontier in genomic and epigenetic research on liver cancer Chairs: Snorri Thorgeirsson, MD, PhD (USA) and Peter Schirmacher, MD (Germany)
09:00 – 11:00	• Clinical workshop: Diagnosis and curative treatments of HCC Chairs: Vincenzo Mazzaferro, MD (Italy) and Jorge Marrero, MD (USA)
11:15 – 11:30	Opening Ceremony Jordi Bruix, MD (Spain); Josep M Llovet, MD (USA/Spain); Peter Galle, MD (Germany); ILCA Governing Board
11:30 – 13:00	General Session 1: Genomics and signalling pathways Chairs: Marco Pierotti, PhD (Italy) and Peter Galle, MD (Germany) O-001 Sorafenib inhibits IL-6 induced STAT3 signaling by induction of phosphatase SHP2 in cholangiocarcinoma Boris R. A. Blechacz³, Rory L. Smoot³, Steven F. Bronk³, Nathan W. Werneburg³, Scott M. Wilhelm¹, Alphonse E. Sirica², Gregory J. Gores³ ¹, Bayer HealthCare Pharmaceuticals, Montville, ², Virginia Commonwealth University School of Medicine, Richmond, ³Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, United States O-002 Immune cell-related MICRORNA-155 is associated with human liver cirrhosis and hepatocellular carcinoma* Anuradha Budhu¹, Zhipeng Yu¹, Marshonna Forgues¹, Zhao-You Tang², Carlo M. Croce³, Xin W. Wang¹ ¹Laboratory of Human Carcinogenesis, National Institutes of Health, Bethesda, United States, ²Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, ³Comprehensive Cancer Center, Ohio State University, Ohio, United States O-003 MICRORNA (miRNA) expression profiles define a new molecular subclass of hepatocellular carcinoma* Sara Toffanin¹, Anja Lachenmayer¹, Yujin Hoshida², Laia Cabellos¹, Jun Lu², Augusto Villanueva³, Derek Y. Chiang², Beatriz Minguez¹, Radoslav Savic¹, Sasan Roayaie¹, Jordi Bruix³, Myron E. Schwartz¹, Vincenzo Mazzaferro⁴, Samuel Waxman¹, Scott L. Friedman¹, Todd R. Golub², Josep M. Llovet¹ ¹Mount Sinai Liver Cancer Programme, Division of Liver Diseases, Hemato-Oncology and Surgical Oncology, Mount Sinai School of Medicine, New York, ²Cancer Programme, Broad Institute of Harvard and MIT, Cambridge, MA, United States, ³Barcelona-Clinic Liver Cancer Group (BCLC), Liver Unit, CIBERehd, Hospital Clinic, Barcelona, Spain, ⁴Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy O-004 Cancer pathway profiling in experimental tumors derived from immortalised human hepatocytes with aberrant wnt/beta-catenin activation* Henning Wege¹, Denise Heim¹, Ansgar W. Lohse¹, Tim H. Bruemmendorf² ¹Department of Gastroenterology and Hepatology, ²Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany* O-005 c-Met is required for stem cell-mediated liver regeneration Valentina M. Factor¹, Tsuyoshi Ishikawa¹, Jens U. Marquardt¹, Chiara Raggi¹, Elizabeth A. Conner¹, Snorri S. Thorgeirsson¹ ¹Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, United States* O-006 Kupffer cell suppression of intratumoral T cell effector responses is mediated by B7-H1 and PD-1 interactions in human hepatocellular carcinoma (HCC) Theodore H. Welling¹, Ke Wu¹, Ilona Kryczek¹, Jorge A. Marrero², Weiping Zou¹ ¹Surgery, ²Internal Medicine, University of Michigan Health System, Ann Arbor, United States*
13:00 – 13:15	Session Break
13:15 – 14:15	Bayer Symposium: Setting New Standards in HCC: From Diagnosis to Treatment Chair: Jordi Bruix, MD (Spain) • Introduction Jordi Bruix, MD (Spain) • Why Hepatocyte Specific Imaging in Liver Diagnosis? Jens Ricke, MD (Germany) • Recurrent HCC After Curative Treatments: Adjuvant Strategies to Address an Unmet Need Vincenzo Mazzaferro, MD (Italy) • Best Practices and Treatment Options in Intermediate-stage HCC in the Era of Systemic Therapy Riccardo Lencioni, MD (Italy) • Future Prospects on Molecular Targeted Therapies in HCC Josep M Llovet, MD (USA/Spain) • Panel Discussion and Audience Q&A Jordi Bruix, MD (Spain) • Closing Remarks and Conclusions Jordi Bruix, MD (Spain)
14:15 – 15:00	State of the Art Basic Lecture: Molecular drivers of benign liver tumors Introduction and perspective: Snorri Thorgeirsson, MD, PhD (USA) Speaker: Jessica Zucman-Rossi, MD, PhD (France)
15:00 – 17:00	ILCA Symposium 1: Hepatocellular carcinoma: identifying targets for novel therapies Chairs: Josep M Llovet, MD (USA/Spain) and Eric Raymond, MD (France) • Experimental data with pipeline drugs in HCC Jean Francois Dufour, MD (Switzerland) • Linking signalling pathways and molecular therapies in HCC Josep M Llovet, MD (USA/Spain) • Biomarkers and imaging end-points with targeted therapies Andrew Zhu, MD (USA) • Comparing results with targeted therapies: HCC vs. other cancers Sandrine Faivre, MD (France)
17:00 – 17:30	Coffee and Networking Break
17:30 – 19:00	General Session 2: Biomarkers and novel targets Chairs: Didier Samuel, MD (France) and Ronnie Poon, MD (China) O-007 Glucose intolerance is an independent risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C Hirokazu Takahashi¹, Toshihiko Mizuta¹, Takuya Kuwashiro¹, Satoshi Ooeda¹, Noriko Ooza¹, Hiroshi Hamajima¹, Yasunori Kawaguchi¹, Yuichirou Eguchi¹, Iwata Ozaki¹, Kazuma Fujimoto¹ ¹Internal Medicine, Saga University, Saga, Japan* O-008 Optimisation of CT imaging protocols for characterising small (1-2 cm) nodules in HCC surveillance population Hyun-Jung Jang¹, Korosh Khalili¹, Masoom Haider¹, Seong Ho Park², Tae Kyoung Kim¹ ¹Medical Imaging, University of Toronto, Toronto, Canada, ²Radiology, Asan Medical Center, Seoul, South Korea* O-009 Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells Zhen Fan Yang¹, Sheung Tat Fan¹, David W. Y. Ho¹, Wan Ching Yu¹, Chi Keung Lau¹, Michael N. P. Ng¹, Chun Yip Lam¹ ¹Department of Surgery, The University of Hong Kong, Hong Kong, China* O-010 High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma Yang Xu¹, Xinrong Yang¹, Jia Fan¹ ¹Liver cancer institute, Zhongshan Hospital,Fudan University, Shanghai, China* O-011 The novel pan-deacetylase inhibitor panobinostat induces alternative pathways of apoptosis in hepatocellular carcinoma models Pietro Di Fazio¹, Karl Quint¹, Abbas Agaimy², Claudia Steindorf¹, Regine Schneider-Stock², Daniel Neureiter³, Matthias Ocker¹ ¹Medicine 1, ²Pathology, University Hospital Erlangen, Erlangen, Germany, ³Pathology, Paracelsus Private Medical University, Salzburg, Austria* O-012 Genomic and epigenetic based prediction of response to zebularine therapy in human liver cancer Jesper B. Andersen¹, Chiara Raggi¹, Jens U. Marquardt¹, Elisabeth A. Conner¹, Yun-Han Lee¹, Valentina M. Factor¹, Snorri S. Thorgeirsson¹ ¹Laboratory of Experimental Carcinogenesis, National Cancer Institute NIH, Bethesda, United States*
19:00	Welcome Reception / Social Event

TIME	Saturday, 5 September
07:30 – 08:30	Early Morning Workshops • New trends in interventional oncology for liver tumours Chairs: Riccardo Lencioni, MD (Italy) and Riad Salem, MD (USA) • Guidelines for research and management of HCC Chairs: Morris Sherman, MD (Canada) and Andrew Zhu, MD (USA) • Liver Transplantation for Rare Tumors in Adult Recipients Chairs: Pierre-Alain Clavien, MD (Switzerland) and Vincenzo Mazzaferro, MD (Italy) • Apoptotic and interleukin pathways in HCC Chairs: Lewis Roberts, PhD (USA) and Jesus Prieto, MD (Spain)
08:30 – 09:00	Special Lecture 1: Systemic regulation of HCC cancer development and progression Speaker: Jianren Gu, PhD (P.R. China)
09.00 - 10.30	General Session 3: Curative therapies Chairs: Kim Olthoff, MD (USA) and Pietro Majno, MD (Switzerland) O-013 Characterisation of small (1-2 cm) hepatic nodules in HCC screening population: analysis of multiple imaging parameters of Gd-BOPTA-enhanced MR imaging Tae Kyoung Kim¹, Korosh Khalili¹, Masoom Haider¹, Seong Ho Park², Hyun-Jung Jang¹ ¹Medical Imaging, University of Toronto, Toronto, Canada, ²Radiology, Asan Medical Center, Seoul, South Korea* O-014 Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan and UCSF criteria Carole Macaron¹, Ibrahim A. Hanouneh¹, Federico Aucejo², Rocio Lopez³, Nizar N. Zein⁴ ¹Internal Medicine, ²General Surgery, Transplant Center, ³Quantitative Health Sciences, ⁴Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, United States* O-015 Predictors of mortality among patients with perihilar cholangiocarcinoma William Sanchez¹, Joseph Kaiya², Lewis R. Roberts², Gregory J. Gores² ¹Miles and Shirley Fiterman Center for Digestive Diseases, ²Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States* O-016 Systematic review of randomised and nonrandomised trials on the clinical efficacy and safety of neoadjuvant transarterial chemoembolisation for resectable hepatocelluar carcinoma Terence C. Chua¹, Winston Liauw², Akshat Saxena¹, Francis Chu¹, Derek Glenn³, Alan Chai³, David L. Morris¹ ¹Department of Surgery, ²Department of Medical Oncology, ³Department of Radiology, St George Hospital, Sydney, Australia* O-017 Long-term results of liver transplantation for hepatocellular carcinoma in 15 HIV+ patients Eric Vibert¹, Jean-Charles Duclos-Vallee², Maria Rosa Ghigna³, Catherine Guettier³, Daniel Azoulay¹, Denis Castaing¹, Didier Samuel⁴, Rene Adam¹ ¹Centre Hepato-Biliaire, AP-HP Hopital Paul Brousse, ²U 785, INSERM, Villejuif, ³Laboratoire Anatomie Pathologique, AP-HP Hopital de Bicetre, Le Kremlin-Bicetre, ⁴UMR-S785, Univ Paris-Sud, Villejuif, France O-018 Clinical characteristics and prognosis of treatment-naive 1,471 patients with hepatocellular carcinoma: 5-year experience of single institute* Kwang-Hyub Han¹, Seung Up Kim*¹, Jun Yong Park¹, Do Young Kim¹, Sang Hoon Ahn¹, Chae Yoon Chon¹, Jinsil Seong², Do Youn Lee³, Jong Tae Lee³, Kyung Sik Kim⁴, Jin Sub Choi⁴ ¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, ²Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea, ³Department of Radiology, Yonsei University College of Medicine, Seoul, Korea, ⁴Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Severance Hospital, Seoul, South Korea
10:30 – 11:00	Coffee and Networking Break
11:00 – 12:30	ILCA Plenary General Session Chairs: Massimo Colombo, MD (Italy) and Nelson Fausto, MD (USA) ILCA Report Josep M Llovet, MD (USA/Spain) O-019 Signal pathways during HCC pathogenesis: from genomics to mouse models Susie Lee¹, Coral Ho¹, Deigo Calvisi², Xin Chen¹ ¹Biopharmaceutical Sciences, UCSF, San Francisco, United States, ²Pathology, University of Greifswald, Greifswald, Germany* O-020 Gene-expression signature predicts development of hepatocellular carcinoma and survival in cirrhotic patients Yujin Hoshida¹, Augusto Villanueva², Angelo Sangiovanni³, Manel Sole², Joshua Gould¹, Supriya Gupta⁴, Stacey Gabriel⁴, Judit Peix², Massimo Colombo³, Josep M. Llovet², Todd R. Golub¹ ¹Cancer Programme, Broad Institute, Cambridge, United States, ²HCC Translational Research Lab, BCLC-Group, IDIBAPS, CIBERHED, Hospital Clínic, Barcelona, Spain, ³Department of Gastroenterology and Endocrinology, A.M. & A. Migliavacca Center for Liver Disease, FIRC Unit on Liver Cancer, IRCCS Maggiore Hospital a, Milan, Italy, ⁴Genetic Analysis Platform, Broad Institute, Cambridge, United States O-021 Integrating genomic and transcriptional aberrations in hepatoblastoma Carolina Armengol¹, Emilie Thomas², Stefano Cairo³, Aurélien de Reyniès², Monique Fabre⁴, Marie Annick Buendia³ ¹Hepatology Unit, Health Science Research Institute. Germans Trias i Pujol Foundation. CIBERehd, Badalona, Spain, ²Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, ³Oncogenesis and Molecular Virology Unit, Institut Pasteur. INSERM U579, ⁴Service d'Anatomie et de Cytologie Pathologiques, Université Paris-Sud 11, APHP Hôpital de Bicêtre, Paris, France O-022 Pegintron maintenance therapy in cirrhotic (metavir F4) HCV patients who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial J Bruix¹, T Poynard², M Colombo³, E Schiff⁴, J Reichen⁵, K Burak⁶, E Heathcote⁷, T Berg⁸, J Poo-Ramirez⁹, C Brandao Mello¹⁰, R Guenther¹¹, C Niederau1², R Terg1³, N Boparai1⁴, J Harvey1⁴, L Griffel1⁴, M Burroughs1⁴, C Brass1⁴, J Albrecht1⁴ ¹, U Barcelona, Barcelona, Spain, ², Hopital La Petie Salpetriere, Paris, France, ³, Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy, ⁴, U Miami, Miami, United States, ⁵, U Bern, Bern, Switzerland, ⁶, U Calgary, Calgary, ⁷, Toronto Western Hosp, Toronto, Canada, ⁸, Charite Campus Virchow Klinikum, Berlin, Germany, ⁹, Hosp Medica Sur, Mexico City, Mexico, ¹⁰, Hosp U Gaffree Guinle, Rio de Janeiro, Brazil, ¹¹, U Schleswig-Holstein, Kiel, ¹², St Josef Hosp, Oberhausen, Germany, ¹³, Hosp Municipal De Gastroenerologia, Buenos Aires, Argentina, ¹⁴, Schering-Plough Research Institute, Kenilworth, United States O-023 Transcatheter arterial chemoembolisation for unresectable hapatocellular carcinoma: a long term outcomes and prognostic factor analysis with 1816 patients* Zheng-Gang Ren¹, Jing-Lin Xia¹, Yu-Hong Gan¹, Ning-Ling Ge¹, Yi Chen¹, Bo-Heng Zhang¹, Yan-Hong Wang¹, Sheng-Long Ye¹ ¹Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China*
12:30 – 13:00	ILCA President’s Farewell Note: Present and future research in HCC Introduction and perspective: Greg Gores, MD (USA) Speaker: Jordi Bruix, MD (Spain)
13:15 – 14:15	Novartis Oncology Symposium: Improving Clinical Outcomes: The Emerging Role of mTOR Inhibition in HCC Chair: Ronnie Poon, MD (PR China) • Welcome and Introduction Ronnie Poon, MD (PR China) • Retrospective: Current Trends and Unmet Needs in the Management of Advanced Hepatocellular Carcinoma Ronnie Poon, MD (PR China) • mTOR as a Novel Target in Hepatocellular Carcinoma Jean-Francois Dufour, MD (Switzerland) • Emerging Clinical Evidence for RAD001 in Advanced Hepatocellular Carcinoma Li-Tzong Chen, MD, PhD (Taiwan) • Panel Discussion and Audience Q&A Ronnie Poon, MD (PR China) • Closing Remarks and Conclusions Ronnie Poon, MD (PR China) Terumo/Biocompatibles Symposium: DC Bead in the Treatment of Hepatocellular Carcinoma: Where Do We Stand? Chair: Jordi Bruix, MD (Spain) • Rationale of PRECISION TACE with Drug-Eluting Bead Thomas Vogl, MD (Germany) • Transarterial Chemoembolisation for Hepatocellular Carcinoma: Lessons Learned from Randomised Trials Riccardo Lencioni, MD (Italy) • DEB-TACE Versus Conventional TACE for HCC in Patient Awaiting Liver Transplantation: Preliminary Results of a Randomised Trial Thomas Kröncke, MD (Germany) • Panel Discussion and Audience Q&A Jordi Bruix, MD (Spain) • Closing Remarks and Conclusions Jordi Bruix, MD (Spain)
14:15 – 15:00	Poster Viewing Session Chairs: Jordi Bruix, MD (Spain) and Marie Annick Buendia, MD (France)
15:00 – 15:30	Special Lecture 2: Pathogenesis of liver fibrosis: milieu for HCC development Speaker: Scott Friedman, MD (USA)
15:30 – 16:00	Coffee and Networking Break
16:00 – 17:30	General Session 4: Loco-regional therapies Chairs: Michel Beaugrand, MD (France) and Masatoshi Kudo, MD, PhD (Japan) O-024 Contrast enhanced ultrasound of intrahepatic peripheral cholangiocarcinoma in cirrhotic patients Alejandro Forner¹, Ramon Vilana², Luis Bianchi², Ángeles García-Criado², Jordi Rimola², Carlos Rodríguez de Lope¹, María E. Reig¹, Carmen Ayuso², Concepció Bru², Jordi Bruix¹ ¹Liver Unit. BCLC group, ²Radiology Department. BCLC group, Hospital Clinic. IDIBAPS. CIBERahd., Barcelona, Spain* O-025 Reduced liver toxicity in intermediate-stage hepatocellular carcinoma patients treated by chemoembolisation with drug eluting bead: results from the PRECISION V randomised trial Riccardo Lencioni¹, Katerina Malagari², Thomas Vogl³, Frank Pilleul⁴, Alban Denys⁵, Anthony Watkinson⁶, Johannes Lammer⁷ ¹Diagnostic Imaging and Intervention, University of Pisa, Pisa, Italy, ²Radiology, University of Athens, Athens, Greece, ³Radiology, University of Frankfurt, Frankfurt, Germany, ⁴Radiology, Centre Hospitalier Universitaire, Lyon, France, ⁵Radiology, Centre Hospitalier Universitaire, Lausanne, Switzerland, ⁶Radiology, Royal Devon and Exeter Hospital, Exeter, United Kingdom, ⁷Radiology, University of Vienna, Vienna, Austria O-026 Toxicity of Y90-radioembolisation resulting from radiation of non-target tissues* Mercedes Iñarrairaegui¹, Delia D'Avola², José I. Bilbao³, Javier Rodriguez⁴, Maria M. Rodriguez⁵, Antonio Martinez De La Cuesta³, Felix Alegre¹, José I. Herrero², Jorge Quiroga², Jesus Prieto², Bruno Sangro² ¹Liver Unit, ²Liver Unit and CIBERehd, ³Radiology, ⁴Oncology, ⁵Nuclear Medicine, Clinica Universitaria, Pamplona, Spain* O-027 Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): subset analysis of the Asia-Pacific (AP) study Shukui Qin¹, Tsai-Sheng Yang², Won-Young Tak³, Shiying Yu⁴, Chao-Jung Tsao⁵, Jun Suk Kim⁶, Karin Burock⁷, Jessie Zou⁸, Dimitris Voliotis⁹, Ann-Lii Cheng¹⁰ ¹Oncology, Nanjing 81 Hospital, Nanjing, China, ², Chang Gung Memorial Hospital, Linkou, Taiwan, ³, Kyungpook National University Hospital, Daegu, South Korea, ⁴, Tongji Hospital, Tongji Medical College, Wuhan, China, ⁵, Chi Mei Medical Center, Liou Ying Campus, Tainan, Taiwan, ⁶, Korea University Guro Hospital, Seoul, South Korea, ⁷, Bayer Schering Pharma, Wuppertal, Germany, ⁸, Bayer Schering Pharma, Shanghai, China, ⁹, Bayer HealthCare Pharmaceuticals, Montville, United States, ¹⁰, National Taiwan University Hospital, Taipei, Taiwan O-028 Efficacy of high-dose conformal radiotherapy (CRT) combined to transarterial chemoembolisation (TACE) for single hepatocellular carcinoma (HCC) nodule* Philippe Merle¹, Marie Cuinet², Denis Marion², Emmanuel Maillard¹, Virginie Wautot³, Christian Trepo¹, Fabien Zoulim¹, Françoise Mornex³ ¹Hepatology, ²Radiology, Hotel-Dieu, ³Radiotherapy, Lyon Sud, Lyon, France* O-029 Phase II trial of bevacizumab combined with transarterial chemoembolisation (TACE) for hepatocellular carcinoma: initial experience at two institutions Diane K. Reyes*¹, Josephina A. Vossen¹, Ihab R. Kamel¹, Mary F. Mulcahy², Riad Salem³, Wells Messersmith⁴, Colin D. Weekes⁴, Christos S. Georgiades¹, Kelvin Hong¹, Jean-Francois H. Geschwind¹ ¹Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, ²Department of Hematology / Oncology, ³Department of Radiology, Northwestern University Medical School, Chicago, ⁴Department of Medical Oncology, University of Colorado Denver, School of Medicine, Denver, United States
17:45 – 18:45	Bracco Symposium: The New Modality - Contrast-Enhanced UltraSound (CEUS) in Liver Imaging Chairs: Riccardo Lencioni, MD (Italy) and Vincenzo Mazzaferro, MD (Italy) • What Clinicians Need to Know about Liver Imaging Vincenzo Mazzaferro, MD (Italy) • Guidelines on the Use of CEUS Modality for Focal Liver Lesions Imaging Riccardo Lencioni, MD (Italy) • Modality in the Management of Nodules in Cirrhosis Fabio Piscaglia, MD (Italy) • CEUS - The Real Time Modality for Early Assessment of Liver Tumour Treatment Response Mohamed Chebil, MD (France) • Final Discussion and Conclusions Sirtex Symposium: Improving Outcomes for Patients with Unresectable HCC: the Role of Radioembolisation Chair: Luigi Bolondi, PhD (Italy) • Introduction and Welcome Luigi Bolondi, PhD (Italy) • Clinical Outcomes from Sir-Spheres Radioembolisation in Unresectable HCC Bruno Sangro, PhD (Spain) • Clinical Trials Using Sir-Spheres, Alone and in Combination with Systemic Therapy Jens Ricke, PhD (Germany) • Panel Discussion and Audience Q&A Luigi Bolondi, PhD (Italy) • Closing Remarks and Conclusions Luigi Bolondi, PhD (Italy)
18:45 – 19:15	ILCA Business Meeting

TIME	Sunday, 6 September
07:30 – 8:30	Early Morning Workshops • Novel concepts in pre-neoplastic lesions Chairs: Masamichi Kojiro, MD (Japan) and Tania Roskams, MD (Belgium) • Etiology and pathway activation in HCC Chairs: Curtis Harris, MD (USA) and Massimo Levrero, MD (Italy) • Future of chemotherapy in liver cancer Chairs: Eric Raymond, MD (France) and Tim Meyer, MD (UK)
08:30 – 09:00	Special Lecture 4: Progress in liver regeneration and liver cancer research Speaker: Nelson Fausto, MD (USA)
09:00 – 11:00	ILCA Symposium 2: Cholangiocarcinoma: from genomics to therapy Chairs: Gregory Gores, MD (USA) and Jessica Zucman-Rossi, MD, PhD (France) • Pathogenesis of cholangiocarcinoma Gregory Gores, MD (USA) • Surveillance for early detection and diagnosis Kirsten M. Boberg, MD, PhD (Norway) • Surgical approach for the treatment of cholangiocarcinoma Pierre-Alain Clavien, MD (Switzerland) • Systemic therapies: what can be tested Chris Verslype, MD, PhD (Belgium)
11:00 – 11:30	Coffee and Networking Break
11:30- 12:15:	State of the Art Clinical Lecture: Epidemiological perspective: HBV vaccinations and implications in HCC development Introduction and perspective: Morris Sherman, MD (Canada) Speaker: Ann-Lii Cheng, MD (Taiwan)
12:15 – 13:45	General Session 5: Novel Therapies Chairs: Ann-Lii Cheng, MD (Taiwan) and Sheng-Long Ye, MD (P.R. China) O-030 Phase 2 study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) Jean-Luc Raoul¹, Richard S. Finn², Yoon-Koo Kang³, Joong-Won Park⁴, Rosemarie Harris⁵, Vlad Coric⁵, Christine Baudelet⁵, Ian Walters⁵ ¹Dept d Oncologie Medicale, Centre E Marquis, Rennes, France, ²Geffen School of Medicine, UCLA, Los Angeles, United States, ³University of Ulsan College of Medicine, Asan Medical Center, Seoul, ⁴, National Cancer Center, Goyang, South Korea, ⁵, Bristol-Myers Squibb, Princeton, United States O-031 Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma* Ahmed O. Kaseb¹, Michiko Iwasaki¹, Milind Javle², Georgiana Onicescu³, Elizabeth Garrett-Mayer⁴, James Abbruzzese¹, Melanie Thomas⁴ ¹GI Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, United States, ², , ³Department of Biostatistics, ⁴Medical Oncology, Hollings Cancer Center, Charleston, United States O-032 Menatetrenone, a vitamin K2 analog, tends to suppress recurrence of hepatocellular carcinoma in patients undergo surgical resection – a randomised prospective study* Tokihiko Sawada¹, Masato Kato¹, Junji Kita¹, Mitsugi Shimoda¹, Keiichi Kubota¹ ¹Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan* O-033 Survival of patients treated with Yttrium-90 radioembolisation vs chemoembolisation for unresectable hepatocellular carcinoma Laura E. Moreno Luna¹, William Sanchez², Andrews C. James³, Gregory A. Wiseman³, Lewis R. Roberts² ¹Gastroenterology and Hepatology, mayo clinic, rochester, ²Gastroenterology and Hepatology, ³Radiology, Mayo Clinic, Rochester, United States* O-034 Open-label, multicenter phase 2 trial of ABT-869 in advanced hepatocellular carcinoma (HCC) patients: prognostic factors. Wei-Peng Yong¹, Pei-Jer Chen², Jennifer Knox³, Sharlene Gill⁴, Dawn Carlson⁵, Jiang Qian⁶, Qin Qin⁶, Justin Ricker⁵, Han-Chong Toh⁷ ¹Department of Haematology-Oncology, National University Hospital, Singapore, Singapore, ²Division of Digestive Diseases, National Taiwan University Hospital, Taipei, Taiwan, ³Department Medical Oncology, Princess Margaret Hospital, Tornto, ⁴Department Advanced Therapeutics, British Columbia Cancer Center, Vancouver, Canada, ⁵Oncology, ⁶Global Statistics and Data Management, Abbott Laboratories, Abbott Park, United States, ⁷Department Medical Oncology, National Cancer Centre Singapore, Republic of Singapore O-035 Inhibition of the TGF-beta1 pathway as a new anti-stromal therapy in hepatocellular carcinoma* Antonio Mazzocca¹, Emilia Fransvea¹, Rosa Maritato¹, Francesca Baldassarre¹, Salvatore Antonaci¹, Gianluigi Giannelli¹ ¹Internal Medicine, Immunology and Infectious Diseases, University of Bari, Medical School, Bari, Italy*
13:45	Closing Ceremony

Conference

ILCA 2010
Conference Webcast

ILCA 2009
Conference Webcast

Membership

ILCA – an International and Multi-disciplinary Association for Liver Cancer Experts
Find out more about ILCA Member Benefits and how to become a member.

Association

Mission
The International Liver Cancer Association (ILCA) aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer.